

TARGANTA APPOINTS WILLIAM CROUSE TO BOARD OF DIRECTORS

Indianapolis, Indiana & St. Laurent, Quebec, January 25, 2006 – Targanta Therapeutics, a privately held biopharmaceutical company developing antibacterial drugs, announced today that William W. Crouse has joined its board of directors. With his election, Mr. Crouse becomes the seventh member of the Company's board.

William Crouse brings to Targanta 35 years of experience as a private equity investor and senior executive in the life sciences industry. Since 1994, Mr. Crouse has been a General Partner of HealthCare Ventures, one of the world's largest venture capital firms specializing in health care. Prior to joining HealthCare Ventures, he was Worldwide President of Ortho Diagnostic Systems and a Vice President of Johnson & Johnson International. Mr. Crouse also currently sits on the boards of The Medicines Company and ImClone Systems Incorporated.

"Bill brings significant expertise and knowledge to Targanta's board," said Pierre Etienne, M.D., Targanta's President and CEO. "His experience with large health care companies, as well as his hands-on experience from working with dozens of early stage and emerging biopharmaceutical companies, will be a tremendous asset as Targanta prepares to continue the development and registration of our lead product, oritavancin."

During his distinguished career, Mr. Crouse was also Division Director of DuPont Pharmaceuticals, where he was responsible for international operations and worldwide commercial development activities. He also previously served as President of Revlon Health Care Group's companies in Latin America, Canada, and Asia/Pacific.

About Targanta Therapeutics

Targanta Therapeutics is a privately held biopharmaceutical company developing and commercializing antibacterial drugs to treat serious infections in the hospital setting. Its pipeline includes an array of antibacterial agents in various stages of development. Its lead product, oritavancin, used to treat Gram-positive bacterial infections, has completed two Phase III clinical trials. The company is headquartered in Indianapolis, Indiana, and maintains research and development operations in St. Laurent, Quebec. The company's venture capital investors include Seaflower

Ventures, VenGrowth Private Equity Partners, MDS Capital, and T2C2/Bio. For more information about the company, please visit, www.targanta.com.

#

Contact:
Julie Huang
Financial Dynamics
(212) 850-5628
jhuang@fd-us.com